Antiepileptic effects of two Rho-kinase inhibitors, Y-27632 and fasudil, in mice

British Journal of Pharmacology

Volumn 155, Issue 1, 2008, Pages 44-51

  Inan, S Y ^a   Buyukafsar K ^a  

^a MERSIN UNIVERSITY   (Turkey)

Author keywords

Epilepsy; Fasudil; Rho Rho kinase signalling; Seizure; Y 27632

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ANTICONVULSIVE AGENT; FASUDIL; PENTETRAZOLE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BRAIN; CONTROLLED STUDY; CONVULSION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFECT; ELECTRIC SHOCK; ENZYME INHIBITION; EPILEPSY; EPILEPTOGENESIS; KINDLING; MOTOR COORDINATION; MOUSE; MYOCLONUS SEIZURE; NONHUMAN; PRIORITY JOURNAL; REPEATED DRUG DOSE; RIGHTING REFLEX; ROTAROD TEST; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TONIC CLONIC SEIZURE; TREATMENT OUTCOME; WESTERN BLOTTING;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; AMIDES; ANIMALS; ANTICONVULSANTS; BLOTTING, WESTERN; BRAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; KINDLING, NEUROLOGIC; MALE; MICE; MOTOR ACTIVITY; PENTYLENETETRAZOLE; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; PYRIDINES; REFLEX; RHO-ASSOCIATED KINASES; SEIZURES;

EID: 50249104353     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.225     Document Type: Article

References (52)

1. 2+ channel blockade with nifedipine. Eur J Pharmacol 254: 9-16.
2. Borisoff JF, Chan CC, Hiebert GW, Oschipok L, Robertson GS, Zamboni R et al. (2003). Suppression of Rho-kinase activity promotes axonal growth on inhibitory CNS substrates. Mol Cell Neurosci 22: 405-416.
3. Büyükafşar K, Akça T, Tiftik RN, Şahan-Firat S, Aydin S (2006b). Contribution of Rho-kinase in human gallbladder contractions. Eur J Pharmacol 540: 162-167.
4. Büyükafşar K, Levent A (2003). Involvement of Rho/Rho-kinase signalling in the contractile activity and acetylcholine release in the mouse gastric fundus. Biochem Biophys Res Commun 303: 777-781.
5. Büyükafşar K, Levent A, Ark M (2003). Expression of Rho-kinase and its functional role in the contractile activity of the mouse vas deferens. Br J Pharmacol 140: 743-749.
6. Büyükafşar K, Yalçin I, Kurt AH, Tiftik RN, Şahan-Firat S, Aksu F (2006a). Rho-kinase inhibitor, Y-27632, has an antinociceptive effect in mice. Eur J Pharmacol 541: 49-52.
7. Carter DS, Haider SN, Blair RE, Deshpande LS, Sombati S, DeLorenzo RJ (2006). Altered calcium/calmodulin kinase II activity changes calcium homeostasis that underlies epileptiform activity in hippocampal neurons in culture. J Pharmacol Exp Ther 319: 1021-1031.
8. Dash PK, Orsi SA, Moody M, Moore AN (2004). A role for hippocampal Rho-ROCK pathway in long-term spatial memory. Biochem Biophys Res Commun 322: 893-898.
9. Davies SP, Reddy H, Caivano M, Cohen P (2000). Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
10. Dubreuil CI, Marklund N, Deschamps K, McIntoch TK, McKerracher L (2006). Activation of Rho after traumatic brain injury and seizure in rats. Exp Neurol 198: 361-369.
11. Fischer W, Kittner H (1998). Influence of ethanol on the pentylenetetrazol-induced kindling in rats. J Neural Transm 105: 1129-1142.
12. Fochtmann LJ (1994). Animal studies of electroconvulsive therapy: foundations for future research. Psychopharmacol Bull 30: 321-444.
13. Gale K (1993). Focal trigger zones and pathways of propagation in seizure generation. In: Schwartzkroin PA (ed). Epilepsy: Models, Mechanisms, and Concepts. Cambridge University Press: Cambridge, pp 48-85.
14. Inoue M, Rashid MH, Fujita R, Contos JJ, Chun J, Ueda H (2004). Initiation of neuropathic pain requires lysophosphatidic acid receptor signalling. Nat Med 10: 712-718.
15. Ito K, Hirooka Y, Sakai K, Kishi T, Kaibuchi K, Shimokawa H et al. (2003). Rho/Rho-kinase pathway in brain stem contributes to blood pressure regulation via sympathetic nervous system: possible involvement in neural mechanisms of hypertension. Circ Res 92: 1337-1343.
16. Janjua N, Mayer SA (2003). Cerebral vasospasm after subarachnoid hemorrhage. Curr Opin Crit Care 9: 113-119.
17. Jeon S, Kim S, Park JB, Suh PG, Kim YS, Bae CD et al. (2002). RhoA and Rho kinase-dependent phosphorylation of moesin at Thr-558 in hippocampal neuronal cells by glutamate. J Biol Chem 277: 16576-16584.
18. Jeon SH, Seong YS, Juhnn YS, Kang UG, Ha KS, Kim YS et al. (1997). Electroconvulsive shock increases the phosphorylation of cyclic AMP response element binding protein at Ser-133 in rat hippocampus but not in cerebellum. Neuropharmacology 36: 411-414.
19. Jiang W, Du B, Chi Z, Ma L, Wang S, Zhang X et al. (2007). Preliminary explorations of the role of mitochondrial proteins in refractory epilepsy: some findings from comparative proteomics. J Neurosci Res 85: 3160-3170.
20. Kang UG, Koo YJ, Jeon WJ, Park DB, Juhnn YS, Park JB et al. (2006). Activation of extracellular signal-regulated kinase signalling by chronic electroconvulsive shock in the rat frontal cortex. Psychiatry Res 145: 75-78.
21. Kawabuchi A, Ohmori M, Fujimura A (2004). Partial protective effect of Y-27632, a Rho kinase inhibitor, against hepatic ischemia-reperfusion injury in rats. Eur J Pharmacol 493: 167-171.
22. Kitaoka Y, Kumai T, Lam TT, Kuribayashi K, Isenoumi K, Munemasa Y et al. (2004). Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina. Brain Res 1018: 111-118.
23. Leemhuis J, Boutillier S, Barth H, Feuerstein TJ, Brock C, Nurnberg B et al. (2004). Rho GTPases and phosphoinositide 3-kinase organize formation of branched dendrites. J Biol Chem 279: 585-596.
24. Levent A, Büyükafşar K (2004). Expression of Rho-kinase (ROCK-1 and ROCK-2) and its substantial role in the contractile activity of the sheep ureter. Br J Pharmacol 143: 431-437.
25. Loscher W (2002). Animal models of epilepsy for the development of antiepileptogenic and disease-modifying drugs. A comparison of the pharmacology of kindling and post-status epilepticus models of temporal lobe epilepsy. Epilepsy Res 50: 105-123.
26. Mackay DJ, Hall A (1998). Rho GTPases. J Biol Chem 273: 20685-20688.
27. Mortazavi F, Ericson M, Story D, Hulce VD, Dunbar GL (2005). Spatial learning deficits and emotional impairments in pentylenetetrazole-kindled rats. Epilepsy Behav 7: 629-638.
28. Mueller BK, Mack H, Teusch N (2005). Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov 4: 387-398.
29. Narita M, Takagi M, Aoki K, Kuzumaki N, Suzuki T (2003). Implication of Rho-associated kinase in the elevation of extracellular dopamine levels and its related behaviors induced by methamphetamine in rats. J Neurochem 86: 273-282.
30. O'Kane EM, Stone TW, Morris BJ (2004). Increased long-term potentiation in the CA1 region of rat hippocampus via modulation of GTPase signalling or inhibition of Rho kinase. Neuropharmacology 46: 879-887.
31. Onozuka M, Imai S, Ozono S (1987). Involvement of pentylenetetrazole in synapsin I phosphorylation associated with calcium influx in synaptosomes from rat cerebral cortex. Biochem Pharmacol 36: 1407-1415.
32. Patsalos PN (2000). Anti-epileptic drugs: newly licensed and under development. IDrugs 3: 416-429.
33. Provini F, Plazzi G, Tinuper P, Vandi S, Lugaresi E, Montagna P (1999). Nocturnal frontal lobe epilepsy. A clinical and polygraphic overview of 100 consecutive cases. Brain 122: 1017-1031.
34. Raiteri M (2006). Functional pharmacology in human brain. Pharmacol Rev 58: 162-193.
35. Ramer LM, Borisoff JF, Ramer MS (2004). Rho-kinase inhibition enhances axonal plasticity and attenuates cold hyperalgesia after dorsal rhizotomy. J Neurosci 24: 10796-10805.
36. Şahan-Firat S, Tiftik RN, Nacak M, Büyükafşar K (2005). Rho kinase expression and its central role in ovine gallbladder contractions elicited by a variety of excitatory stimuli. Eur J Pharmacol 528: 169-175.
37. Sakisaka T, Baba T, Tanaka S, Izumi G, Yasumi M, Takai Y (2004). Regulation of SNAREs by tomosyn and ROCK: implication in extension and retraction of neurites. J Cell Biol 166: 17-25.
38. Sasa M (2006). A new frontier in epilepsy: novel antiepileptogenic drugs. J Pharmacol Sci 100: 487-494.
39. Sasaki Y (2003). New aspects of neurotransmitter release and exocytosis: Rho-kinase-dependent myristoylated alanine-rich C-kinase substrate phosphorylation and regulation of neurofilament structure in neuronal cells. J Pharmacol Sci 93: 35-40.
40. Schroder H, Becker A, Lossner B (1993). Glutamate binding to brain membranes is increased in pentylenetetrazole-kindled rats. J Neurochem 60: 1007-1011.
41. Schroder H, Schlichthaar R, Krug M (1994). Specific [3H]L- glutamate binding and [3H]D-aspartate release in the hippocampus of rat after pentylenetetrazol kindling and long-term potentiation. Neuroscience 60: 337-342.
42. Schubert V, Da Silva JS, Dotti CG (2006). Localized recruitment and activation of RhoA underlies dendritic spine morphology in a glutamate receptor-dependent manner. J Cell Biol 172: 453-467.
43. Shibuya M, Hirai S, Seto M, Satoh S, Ohtomo E (2005). Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci 238: 31-39.
44. Stamatovic SM, Keep RF, Kunkel SL, Andjelkovic AV (2003). Potential role of MCP-1 in endothelial cell tight junction 'opening': signalling via Rho and Rho kinase. J Cell Sci 116: 4615-4628.
45. Tatsumi S, Mabuchi T, Katano T, Matsumura S, Abe T, Hidaka H et al. (2005). Involvement of Rho-kinase in inflammatory and neuropathic pain through phosphorylation of myristoylated alanine-rich C-kinase substrate (MARCKS). Neuroscience 131: 491-498.
46. Tsuda M, Suzuki T, Misawa M (1997). Aggravation of DMCM-induced seizure by nitric oxide synthase inhibitors in mice. Life Sci 60: PL339-PL343.
47. Tsushima H, Mori M, Fujiwara N, Moriyama A (2003). Pharmacological characteristics of bombesin receptor mediating hypothermia in the central nervous system of rats. Brain Res 969: 88-94.
48. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T et al. (1997). Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389: 990-994.
49. Van Aelst L, D'Souza-Schorey C (1997). Rho GTPases and signalling networks. Genes Dev 11: 2295-2322.
50. Zhao M, Discipio RG, Wimmer AG, Schraufstatter IU (2006). Regulation of CXCR4-mediated nuclear translocation of extracellular signal-related kinases 1 and 2. Mol Pharmacol 69: 66-75.
51. Zhou Y, Su Y, Li B, Liu F, Ryder JW, Wu X et al. (2003). Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 302: 1215-1217.
52. Zilles K, Qu MS, Kohling R, Speckmann EJ (1999). Ionotropic glutamate and GABA receptors in human epileptic neocortical tissue: quantitative in vitro receptor autoradiography. Neuroscience 94: 1051-1061.